Cinclus Pharma Holding AB (publ) (STO:CINPHA)
Sweden
· Delayed Price · Currency is SEK 17.14
-0.32 (-1.83%)
At close: Mar 6, 2026
Cinclus Pharma Holding AB Company Description
Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China.
The company’s lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease.
It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H.
pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden.
Cinclus Pharma Holding AB (publ)
| Country | Sweden |
| Founded | 2014 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 21 |
| CEO | Christer Ahlberg |
Contact Details
Address: Kungsbron 1 Stockholm, 11122 Sweden | |
| Phone | 46 8 13 33 10 |
| Website | cincluspharma.com |
Stock Details
| Ticker Symbol | CINPHA |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0020388577 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Christer Ahlberg | Chief Executive Officer and President |
| Dr. Lennart Hansson Ph.D. | Co-founder and Chairman of the Board |
| Peter Unge | Co-founder and Member of Scientific Advisory Board |
| Patrik Norgren | Interim Chief Financial Officer |
| Kajsa Larsson | Chief Medical Officer |
| Jesper Wiklund | Chief Business Officer |
| Dr. Margit Mahlapuu Ph.D. | Executive Research & Development Director |
| Peter Wallich | Commercial Director |